Displaying drugs 10951 - 10975 of 11745 in total
BNT162b3
The BNT162b3 vaccine is the latest addition to BioNTech and partner Pfizer’s mRNA COVID-19 vaccine program. Similar to BNT162b2, BNT162b3 uses a nucleoside-modified RNA (modRNA) technology. Pfizer and BioNTech deemed this compound as promising in preclinical trials and have decided to initiate further testing of it. As such, BNT162b3 has...
Investigational
Matched Description: … Similar to [BNT162b2], BNT162b3 uses a nucleoside-modified RNA (modRNA) technology. ... As such, BNT162b3 has entered a phase I/II study in early September 2020 (NCT04537949). …
Prinomastat
Prinomastat is a synthetic hydroxamic acid derivative with potential antineoplastic activity. Prinomastat inhibits matrix metalloproteinases (MMPs) (specifically, MMP-2, 9, 13, and 14), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis. As a lipophilic agent, prinomastat crosses the blood-brain barrier.
Investigational
Matched Description: … As a lipophilic agent, prinomastat crosses the blood-brain barrier. ... Prinomastat is a synthetic hydroxamic acid derivative with potential antineoplastic activity. …
EHT899
EHT899 is a proprietary formulation of an HBV viral protein designed to eliminate the undesirable immune response elicited by the HBV infection. It also apparently enhances a secondary immune response to clear the viral infection, resulting in reduction in liver damage and decrease in viral load.
Investigational
Matched Description: … EHT899 is a proprietary formulation of an HBV viral protein designed to eliminate the undesirable immune ... It also apparently enhances a secondary immune response to clear the viral infection, resulting in reduction …
Edivoxetine
Edivoxetine is a drug which acts as a selective norepinephrine reuptake inhibitor and is currently under development by Eli Lilly for attention-deficit hyperactivity disorder (ADHD) and as an antidepressant treatment. Edivoxetine failed to be approved for major depressive disorder after phase III clinical trials in 2012.
Investigational
Matched Description: … Edivoxetine is a drug which acts as a selective norepinephrine reuptake inhibitor and is currently under …
VY-HTT01
VY-HTT01 is a gene therapy designed to reduce the expression of huntingtin, thereby altering disease progression. VY-HTT01 is comprised of an adeno-associated virus capsid (AAV1) and a proprietary transgene that harnesses the canonical RNA interference pathway to selectively knock down levels of HTT mRNA.
Investigational
Matched Description: … VY-HTT01 is a gene therapy designed to reduce the expression of huntingtin, thereby altering disease ... VY-HTT01 is comprised of an adeno-associated virus capsid (AAV1) and a proprietary transgene that harnesses …
Morphine glucuronide
Investigational
Interleukin-7
Interleukin 7 has been used in trials studying the treatment of Metastatic Breast Cancer.
Investigational
XAV-19
XAV-19 is an intravenous antibody-based treatment targeted towards SARS-CoV-2 and other coronaviruses[L16553,L16558]. The therapy concept is based on COVID-19 convalescent plasma. However, rather than using human plasma, XAV-19 is a heterologous swine glyco-humanized polyclonal antibody that targets the spike protein of SARS-CoV-2[L16553,L16558]. The therapy offers three beneficial effects: the ability...
Investigational
Matched Description: … However, rather than using human plasma, XAV-19 is a heterologous swine glyco-humanized polyclonal antibody ... As of July, 2020, the company is conducting a Phase 2 randomized clinical trial to define dosing safety ... Xenothera has partnered with LFB, a pharmaceutical company, to develop XAV-19, and with Nantes University …
SLx-4090
SLx-4090 is a microsomal triglyceride transfer protein (MTTP) inhibitor potentially for the treatment of type 2 diabetes.
Investigational
Matched Description: … SLx-4090 is a microsomal triglyceride transfer protein (MTTP) inhibitor potentially for the treatment …
Mitemcinal
Mitemcinal (GM-611) is a novel erythromycin-derived prokinetic agent that acts as an agonist at the motilin receptor.
Investigational
Matched Description: … Mitemcinal (GM-611) is a novel erythromycin-derived prokinetic agent that acts as an agonist at the motilin …
β-Hydroxythiofentanyl
β-Hydroxythiofentanyl is an analgesic of the opioid class. This drug is an analog of fentanyl, a potent opioid.
Illicit
Matched Description: … This drug is an analog of fentanyl, a potent opioid. …
Icrucumab
Icrucumab is under investigation in clinical trial NCT01111604 (A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer).
Investigational
Matched Description: … Icrucumab is under investigation in clinical trial NCT01111604 (A Study of IMC-1121B or IMC-18F1 in Colorectal …
MS-1819
MS-1819 is under investigation in clinical trial NCT03481803 (A Phase IIa Study With Escalating Dose of MS1819-SD).
Investigational
Matched Description: … MS-1819 is under investigation in clinical trial NCT03481803 (A Phase IIa Study With Escalating Dose …
GSK-2981278
GSK-2981278 is under investigation in clinical trial NCT03004846 (A Study of GSK2981278 Ointment in Subjects With Plaque Psoriasis).
Investigational
Matched Description: … GSK-2981278 is under investigation in clinical trial NCT03004846 (A Study of GSK2981278 Ointment in Subjects …
Zagotenemab
Zagotenemab is under investigation in clinical trial NCT03518073 (A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease).
Investigational
Matched Description: … Zagotenemab is under investigation in clinical trial NCT03518073 (A Study of LY3303560 in Participants …
NM3086
NM3086 is a recombinant, humanized, aglycosylated, IgG1-kappa anti-properdin monoclonal antibody being developed by Novelmed Therapeutics Inc.
Experimental
Matched Description: … NM3086 is a recombinant, humanized, aglycosylated, IgG1-kappa anti-properdin monoclonal antibody being …
SAR422459
SAR422459 is a Lentiviral Vector Containing The Human Abca4 Gene that is currently being investigated to treat Stargardt disease.
Investigational
Matched Description: … SAR422459 is a Lentiviral Vector Containing The Human Abca4 Gene that is currently being investigated …
BRG01
BRG01 is a genetically modified autologous CAR-T cell therapy under investigation for the treatment of nasopharyngeal carcinoma.
Investigational
Matched Description: … BRG01 is a genetically modified autologous CAR-T cell therapy under investigation for the treatment of …
CTR-107
CTR-107 is a synthetic targeted growth factor. It is being investigated for the treatment of familial exudative vitreoretinopathy.
Investigational
Matched Description: … CTR-107 is a synthetic targeted growth factor. …
RC88
RC88 is an antibody-drug conjugate comprising a humanized anti-mesothelin monoclonal antibody conjugated to monomethyl auristatin E (MMAE).
Investigational
Matched Description: … RC88 is an antibody-drug conjugate comprising a humanized anti-mesothelin monoclonal antibody conjugated …
TAK-071
TAK-071 is under investigation in clinical trial NCT04334317 (A Study of TAK-071 in People With Parkinson Disease).
Investigational
Matched Description: … TAK-071 is under investigation in clinical trial NCT04334317 (A Study of TAK-071 in People With Parkinson …
Beraprost
Beraprost is a synthetic analogue of prostacyclin, under clinical trials for the treatment of pulmonary hypertension. It is also being studied for use in avoiding reperfusion injury.
Investigational
Matched Description: … Beraprost is a synthetic analogue of prostacyclin, under clinical trials for the treatment of pulmonary …
Palifosfamide
Palifosfamide (ZIO-201) is a proprietary stabilized metabolite of ifosfamide. Ifosfamide has been shown to be effective in high doses in treating testicular cancer, sarcoma and lymphoma.
Investigational
Matched Description: … Palifosfamide (ZIO-201) is a proprietary stabilized metabolite of ifosfamide. …
siG12D LODER
siG12D LODER is under investigation in clinical trial NCT01676259 (A Phase 2 Study of Sig12d LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer).
Investigational
Matched Description: … siG12D LODER is under investigation in clinical trial NCT01676259 (A Phase 2 Study of Sig12d LODER in …
ICG-136
ICG-136 is a compound chimeric antigen receptor (cCAR) T-cell therapy developed by iCell Gene Therapeutics. It was investigated for the treatment of acute myeloid leukemia.
Investigational
Matched Description: … ICG-136 is a compound chimeric antigen receptor (cCAR) T-cell therapy developed by iCell Gene Therapeutics …
Displaying drugs 10951 - 10975 of 11745 in total